Leo I. Gordon, MD, on Hodgkin Lymphoma: Management Strategies

2017 NCCN Annual Conference

Leo I. Gordon, MD, of the Robert H. Lurie Comprehensive Cancer Center of Northwestern University, discusses novel immunomodulatory agents and standard treatment options for patients with relapsed or refractory Hodgkin lymphoma.

Ruben A. Mesa, MD, on Myeloproliferative Neoplasms and Myelofibrosis: New Treatment Guidelines

Ruben A. Mesa, MD, of the Mayo Clinic Cance...

Sarcoma

Suzanne George, MD, on Soft-Tissue Sarcoma: Evolving Treatment

Suzanne George, MD, of Dana-Farber Cancer I...

Gynecologic Cancers

ASCO Post

Christina S. Chu, MD, on HPV and Cervical/Vulvar Cancer

Christina S. Chu, MD, of Fox Chase Cancer C...

Pancreatic Cancer

Margaret A. Tempero, MD, on Pancreatic Cancer: Active Systemic Treatment

Margaret A. Tempero, MD, of the UCSF Helen ...

Issues in Oncology

Paul M. Cinciripini, PhD, on Smoking Cessation in Patients With Cancer

Paul M. Cinciripini, PhD, of The University...

Sep

Today In Oncology

Leo I. Gordon, MD, on Hodgkin Lymphoma: Management Strategies

Related Videos

Ruben A. Mesa, MD, on Myeloproliferative Neoplasms and Myelofibrosis: New Treatment Guidelines

Suzanne George, MD, on Soft-Tissue Sarcoma: Evolving Treatment

Christina S. Chu, MD, on HPV and Cervical/Vulvar Cancer

Margaret A. Tempero, MD, on Pancreatic Cancer: Active Systemic Treatment

Paul M. Cinciripini, PhD, on Smoking Cessation in Patients With Cancer

Cost of Treatment, Prior Authorization of Treatment Plans May Cause Barriers to Care

FDA Grants Approval to Lenvatinib/Pembrolizumab in Advanced Endometrial Cancer, Announces Project Orbis

Olaparib Improves Outcomes in Ovarian Cancer

Does PTSD Increase the Risk of Developing Ovarian Cancer?

Does the Addition of Bevacizumab to Erlotinib in Advanced EGFR-Mutant NSCLC Improve PFS?